Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNTO 888 + paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
CNTO 888 is a human monoclonal antibody that targets and neutralizes the chemokine CCL2 (also known as MCP-1), which is implicated in tumor progression and resistance to chemotherapy. Paclitaxel is a microtubule-stabilizing agent that inhibits cell division by preventing microtubule depolymerization, while carboplatin is a platinum-based alkylating agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. The combination of CNTO 888 with paclitaxel and carboplatin has been investigated for its potential to enhance the efficacy of standard chemotherapy regimens—particularly in ovarian cancer—by inhibiting CCL2-mediated mechanisms of drug resistance and tumor growth. This approach aims to improve outcomes in cancers where high levels of CCL2 are associated with poor response to conventional therapies[2][6].
- Other names
- paclitaxelcarboplatin
02
Targets
CCL2 (C-C motif chemokine 2)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on CNTO 888 + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNTO 888 + paclitaxel + carboplatin.